The Pediatric Research Equity Act aims to close the gap in pediatric drug testing but faces significant delays in study completion. Rare disease designations exempt nearly half of new drugs from ...
Please provide your email address to receive an email when new articles are posted on . No drugs approved between 2017 and 2020 were subjected to post-approval pediatric testing requirements. After ...
Please provide your email address to receive an email when new articles are posted on . Out of 323 drugs, only 10% completed testing in children before receiving FDA approval. Rare disease ...
On May 17, the U.S. Food & Drug Administration (“FDA”) issued two important draft guidance documents, which clarify the agency’s approach to requirements and incentives in the realm of pediatric drug ...
Earlier this month, the U.S. Food and Drug Administration (FDA) announced a public meeting entitled “Interested Parties Meeting: Implementation of the Best Pharmaceuticals for Children Act and ...
Mary Carmack is a researcher in the Pediatric Therapeutics and Regulatory Science Initiative in the Computational Health Informatics Program at Boston Children’s Hospital, in Boston, Massachusetts.
Newly approved drugs in Canada lack important pediatric drug information in their product monograph, according to an analysis led by McMaster University and McMaster Children's Hospital. This absence ...
Compassionate use can be the best option for patients who seek treatment and cannot participate in a clinical trial and who have no satisfactory therapeutic alternatives. Pediatric oncologists should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results